HIGH EFFICACY OF THE COMBINATION CHEMOTHERAPY (CT) OF ORAL VINORELBINE (NVBO) AND CAPECITABINE (X) WITH TRASTUZUMAB (H) IN HER2-POSITIVE METASTATIC BREAST CANCER (MBC): UPDATED ANALYSIS OF THE RESULTS OF AN INTERNATIONAL PHASE II TRIAL

被引：0
|
作者：
Chan, A. [1 ]
Ganju, V. [2 ]
Becquart, D. [3 ]
Conte, P. [4 ]
Gil, M. Gil [5 ]
Petruzelka, L. [6 ]
Bernardo, G. [7 ]
Villanova, G. [8 ]
Tubiana-Mathieu, N. [9 ]
机构：
[1] Mt Hosp, Perth, WA, Australia
[2] Frankston Hosp, Melbourne, Vic, Australia
[3] AZ Middelheim, Med Oncol, Antwerp, Belgium
[4] Univ Modena, Univ Hosp, Dept Onc & Hem, I-41100 Modena, Italy
[5] ICO Hosp Duran & Reynals, Lhospitalet De Llobregat, Spain
[6] Gen Fac Hosp, Prague 2, Czech Republic
[7] Fdn S Maugeri, Pavia, Italy
[8] Pierre Fabre Med, Med Affairs Onclo, Boulogne Billancourt, France
[9] CHU Dupuytren, Limoges, France
来源：
ANNALS OF ONCOLOGY | 2008年 / 19卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：68 / 68
页数：1
相关论文
共 50 条
  • [1] Efficacy of oral vinorelbine (NVBo), capecitabine (X) and trastuzumab (H) triple combination (NVBoXH) in HER2-positive metastatic breast cancer (MBC): First results of an international phase II trial
    Chan, A.
    Ganju, V.
    Becquart, D.
    Conte, P.
    Petruzelka, L.
    Aubert, D.
    Villanova, G.
    Tubiana-Mathieu, N.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [2] Final Results of a Phase II Study of the Combination of Oral Vinorelbine (NVBo), Capecitabine (X) and Trastuzumab (H) in HER2-positive Metastatic Breast Cancer (MBC)
    Petruzelka, L.
    Ganju, V.
    Conte, P. F.
    Tubiana-Mathieu, N.
    Majois, F.
    Espie, M.
    Llombart, A.
    Gil Gil, M.
    Villanova, G.
    Chan, A.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 : S110 - S110
  • [3] High efficacy of the combination of oral vinorelbine (NVBo), capecitabine (X) and trastuzumab (H) in HER2-positive metastatic breast cancer (MBC): updated results of an international phase II trial with a median follow-up of 39 months
    Chan, A.
    Ganju, V.
    Becquart, D.
    Conte, P. F.
    Petruzelka, L.
    Gil-Gil, M.
    Morand, M.
    Vaissiere, N.
    Villanova, G.
    Tubiana-Mathieu, N.
    EJC SUPPLEMENTS, 2009, 7 (02): : 277 - 277
  • [4] Multicenter international phase II study of oral vinorelbine (NVBo), capecitabine (X) and trastuzumab (H) triple combination in HER2-positive metastatic breast cancer (MBC): updated results with a longer follow-up
    Chan, A.
    Ganju, V
    Becquart, D.
    Conte, P. F.
    Petruzelka, L.
    Gil-Gil, M.
    Morand, M.
    Vaissiere, N.
    Villanova, G.
    Tubiana-Mathieu, N.
    CANCER RESEARCH, 2009, 69 (02) : 248S - 248S
  • [5] First-line trastuzumab (H), oral vinorelbine (NVBo) and capecitabine (X) combination therapy for HER2-positive metastatic breast cancer (MBC): efficacy and safety in a multinational phase II study
    Chan, A.
    Ganju, V.
    Becquart, D.
    Conte, P. F.
    Petruzelka, L.
    Goedhalss, L.
    Gil, M. Gil
    Bernardoe, G.
    Villanova, G.
    Tubiana-Mathieu, N.
    EJC SUPPLEMENTS, 2008, 6 (07): : 220 - 221
  • [6] Triple combination of oral vinorelbine, capecitabine and trastuzumab as first-line treatment in HER2-positive metastatic breast cancer (MBC): latest results of an international phase II trial
    Chan, A.
    Ganju, V.
    Becquart, D.
    Conte, P. F.
    Petruzelka, L.
    Perrot, O.
    Villanova, G.
    Tubiana-Mathieu, N.
    EJC SUPPLEMENTS, 2007, 5 (04): : 221 - 222
  • [7] An international phase II study of an all-oral combination of oral vinorelbine (NVBo) and capecitabine (X) in HER2-negative metastatic breast cancer (MBC)
    Tubiana-Mathieu, N.
    Bougnoux, P.
    Becquart, D.
    Chan, A.
    Majois, F.
    Espie, M.
    Aubert, D.
    Villanova, G.
    Conte, P. F.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [8] Phase II study of an all-oral combination of oral vinorelbine (NVBo) and capecitabine (X) in HER2-negative metastatic breast cancer (MBC): First results of an international phase II trial.
    Tubiana-Mathieu, N.
    Bougnoux, P.
    Becquart, D.
    Chan, A.
    Majois, F.
    Espie, M.
    Aubert, D.
    Bourlard, T.
    Villanova, G.
    Conte, P-F
    BREAST CANCER RESEARCH AND TREATMENT, 2006, 100 : S280 - S280
  • [9] Phase II study of the combination of oral vinorelbine (NVBo), capecitabine (X), and transtuzumab (H) in HER2-positive, metastatic breast cancer (MBC): Recent analysis of the results with a median follow-up of 44 months.
    Petruzelka, L. B.
    Ganju, V.
    Becquart, D.
    Conte, P. F.
    Tubiana-Mathieu, N.
    Gil, M. J. Gil
    Morand, M.
    Vaissiere, N.
    Villanova, G.
    Chan, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [10] Phase I-II study of oral vinorelbine (NVBO) and capecitabine (X) in metastatic breast cancer (MBC): Results of the phase I trial
    Anton, A.
    Lluch, A.
    Casado, A.
    Provencio, M.
    Munoz, M.
    Lao, J.
    Bermejo, B.
    Paules, A. B.
    Gayo, J.
    Martin, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
12345